Full text
Earnings transcript
Read the complete earnings call transcript.
CAH
Cardinal Health, Inc.
$254.06
0.35
(0.14%)
| Exchange: | NYSE |
| Market Cap: | 58.83B |
| Shares Outstanding: | 42.857M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | Medical – DistributionView industry performance | |||||
| CEO: | Jason Hollar | |||||
| Full Time Employees: | 61344 | |||||
| Address: |
| |||||
| Website: | https://www.cardinalhealth.com |
Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 226,827,000 | 222,578,000 | 254,248,000 |
| Gross Profit | 7,414,000 | 8,168,000 | 9,774,000 |
| EBITDA | 1,962,000 | 3,106,000 | 3,478,000 |
| Operating Income | 1,243,000 | 2,275,000 | 2,613,000 |
| Net Income | 852,000 | 1,561,000 | 1,714,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Total Assets | 45,121,000 | 53,122,000 | 57,299,000 |
| Total Liabilities | 48,333,000 | 55,756,000 | 60,023,000 |
| Total Stockholders Equity | -3,213,000 | -2,781,000 | -2,883,000 |
| Total Debt | 5,092,000 | 8,527,000 | 9,948,000 |
| Cash and Cash Equivalents | 5,133,000 | 3,874,000 | 4,856,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Operating Cash Flow | 3,762,000 | 2,397,000 | 5,174,000 |
| Capital Expenditure | -511,000 | -547,000 | -649,000 |
| Free Cash Flow | 3,251,000 | 1,850,000 | 4,525,000 |
| Net Income | 852,000 | 1,569,000 | 1,705,000 |
| Net Change in Cash | 1,057,000 | -1,259,000 | 982,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2031 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 307,249,913.618 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 323,894,359.066 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 314,212,000 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 7,278,179.206 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 7,724,119.912 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 7,464,709.202 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 4,702,440.259 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 5,035,873.191 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 4,841,910.020 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 7,290,554.662 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 7,685,501.036 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 7,455,753.964 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 20.430 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 21.250 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 19.840 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 8 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 2 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates CAH intrinsic value between $256.16 – $521.23 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about CAH valuation
Is Cardinal Health, Inc. (CAH) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for Cardinal Health, Inc. (CAH) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is CAH a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether CAH trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is CAH’s P/E ratio?
You can see CAH’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for CAH?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is CAH a good long-term investment?
Whether CAH fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
CAH
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0.14
Trading Metrics:
| Open: | 254.44 | Previous Close: | 253.71 | |
| Day Low: | 252.04 | Day High: | 255.56 | |
| Year Low: | 152.46 | Year High: | 258.3 | |
| Price Avg 50: | 234.07 | Price Avg 200: | 219.64 | |
| Volume: | 1.26M | Average Volume: | 2.045M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
